Central retinal vein occlusion: Cetrain risk factors, electroretinography and an experimental treatment model.
The presence of activated protein C resistance, plasma hyperhomocysteinemia and the MTHFR C677T mutation in patients with central retinal vein occlusion were investigated and compared to a control group. Activated protein C resistance was overrepresented in the group of patients less than 50 years of age whereas this was not the case in patients more than 50 years of age. Neither hyperhomocysteine